Recombinant Human IL-13 R alpha 2 Fc Chimera (NS0), CF Summary
Product Specifications
| Human IL-13 R alpha 2 (Cys22 - Leu342) Accession # Q14627 |
TDIEGRMD | Human IgG1 (Pro100 - Lys330) |
6-His tag |
| N-terminus | C-terminus | ||
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
614-INS
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 200 μg/mL in sterile PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Reconstitution Calculator
Background: IL-13 R alpha 2
Interleukin-13 Receptor alpha 2 (IL-13 Ra2), also known as IL-13 Ra’, IL-13 binding protein, and CD213a2, is a widely expressed 55 kDa cytokine receptor that plays an important role in the Th2‑polarized immune responses characteristic of a variety of pathologies including parasitic infections and allergic asthma (1, 2). Mature human IL‑13 Ra2 consists of a 317 amino acid (aa) extracellular domain with three fibronectin type-III domains, a WSxWS motif, a 20 aa transmembrane segment, and a 17 aa cytoplasmic domain (3). Within the ECD, human IL-13 Ra2 shares 64% and 62% aa sequence identity with mouse and rat IL‑13 Ra2, respectively. A 40 kDa 50 kDa soluble form of IL‑13 Ra2 can be generated by MMP-8 mediated shedding (4). The biological effects of IL-13 and IL-4 are closely related in part due to a shared receptor system. IL-13 binds to IL-13 Ra1 which then forms a signaling complex with IL-4 Ra (5, 6). IL-13 Ra2 functions as a decoy receptor by binding and internalizing IL-13 and preventing it from signaling through the IL-13 Ra1/IL-4 Ra complex (3, 7). IL‑13 Ra2 can also block IL-4 induced responses by inhibiting IL-4 bound IL-13 Ra1/IL-4 Ra receptor complexes even though it does not itself bind IL-4 (8, 9). Aside from its decoy function, IL-13-activated IL-13 Ra2 directly promotes the development of tissue fibrosis by inducing the transcription of TGF‑beta (10). Soluble IL-13 Ra2 retains ligand binding capability and attenuates responses to IL-13 but not to IL-4 (8, 11). The up‑regulation of transmembrane and soluble IL-13 Ra2 during Th2‑biased immune responses limits the extent of those responses (12 ‑ 14). IL‑13 Ra2 is expressed in some cancers, and its ability to block IL‑13 and IL‑4 contributes to tumorigenesis and metastasis (9, 15).
- Wynn, T.A. (2003) Annu. Rev. Immunol. 21:425.
- Tabata, Y. et al. (2007) Curr. Allergy Asthma Rep. 7:338.
- Caput, D. et al. (1996) J. Biol. Chem. 271:16921.
- Chen, W. et al. (2008) J. Allergy Clin. Immunol. 122:625.
- Andrews, A.-L. et al. (2006) J. Immunol. 176:7456.
- Zurawski, S.M. et al. (1995) J. Biol. Chem. 270:13869.
- Donaldson, D.D. et al. (1998) J. Immunol. 161:2317.
- Andrews, A.-L. et al. (2006) J. Allergy Clin. Immunol. 118:858.
- Rahaman, S.O. et al. (2002) Cancer Res. 62:1103.
- Fichtner-Feigl, S. et al. (2006) Nat. Med. 12:99.
- Zhang, J.G. et al. (1997) J. Biol. Chem. 272:9474.
- Chiaramonte, M.G. et al. (2003) J. Exp. Med. 197:687.
- Morimoto, M. et al. (2009) J. Immunol. 183:1934.
- Zheng, T. et al. (2008) J. Immunol. 180:522.
- Fujisawa, T. et al. (2009) Cancer Res. 69:8678.
Citations for Recombinant Human IL-13 R alpha 2 Fc Chimera (NS0), CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
4
Citations: Showing 1 - 4
Filter your results:
Filter by:
-
Development of an in vitro potency bioassay for therapeutic IL-13 antagonists: the A-549 cell bioassay.
Authors: Miller R, Sadhukhan R, Wu C
J. Immunol. Methods, 2008-03-07;334(1):134-41.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Effect of IL-13 receptor alpha2 levels on the biological activity of IL-13 variant R110Q.
Authors: Andrews AL, Bucchieri F, Arima K, Izuhara K, Holgate ST, Davies DE, Holloway JW
J. Allergy Clin. Immunol., 2007-06-08;120(1):91-7.
Species: Human
Sample Types: Recombinant Protein
Applications: Surface Plasmon Resonance -
Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.
Authors: Kioi M, Kawakami M, Shimamura T, Husain SR, Puri RK
Cancer, 2006-09-15;107(6):1407-18.
Applications: ELISA (Standard) -
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Authors: Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC
Cancer Res., 2004-12-15;64(24):9160-6.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human IL-13 R alpha 2 Fc Chimera (NS0), CF
There are currently no reviews for this product. Be the first to review Recombinant Human IL-13 R alpha 2 Fc Chimera (NS0), CF and earn rewards!
Have you used Recombinant Human IL-13 R alpha 2 Fc Chimera (NS0), CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
